Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea

Psychopharmacology

Volumn 233, Issue 2, 2016, Pages 243-254

  Brierley, Daniel I ^a   Samuels, James ^a   Duncan, Marnie ^b   Whalley, Benjamin J ^a   Williams, Claire M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b Porton Down Science Park   (United Kingdom)

Author keywords

Anticipatory nausea; Anxiety; Appetite; Cannabidiolic acid; Cannabinoid; Chemotherapy; Novelty suppressed feeding; Open field; Tolerability; WAY 100 635

Indexed keywords

CANNABIDIOLIC ACID; CANNABINOID; SEROTONIN 1 ANTAGONIST; UNCLASSIFIED DRUG; WAY 100 635; ANXIOLYTIC AGENT; SEROTONIN 1A RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANTICIPATORY NAUSEA AND VOMITING; ARTICLE; DRUG TOLERABILITY; EXPLORATORY BEHAVIOR TEST; FEEDING BEHAVIOR; GRIP STRENGTH TEST; LIGHT DARK BOX TEST; LISTER HOODED RAT; LOCOMOTION; MALE; MOTOR COORDINATION; MUSCLE STRENGTH; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; STATIC BEAM TEST; TRANQUILIZING ACTIVITY; YOUNG ADULT; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; DOSE RESPONSE; DRUG EFFECTS; HAND STRENGTH; MOTOR ACTIVITY; NAUSEA; PREVENTION AND CONTROL; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; HAND STRENGTH; MALE; MOTOR ACTIVITY; MUSCLE STRENGTH; NAUSEA; PSYCHOMOTOR PERFORMANCE; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 84952900532     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-4100-1     Document Type: Article

References (56)

1. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V (2003) Assessment and management of cancer-related fatigue in adults. Lancet 362:640-650. doi: 10.1016/S0140-6736(03)14186-4
2. Basch E, Prestrud AA, Hesketh PJ et al (2012) Antiemetic use in oncology: updated guideline recommendations from ASCO. Am Soc Clin Oncol Educ Book 532:532-540. doi: 10.14694/EdBook-AM.2012.32.532
3. Bolognini D, Rock EM, Cluny NL et al (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456-1470. doi: 10.1111/bph.12043
4. Bourin M, Hascoët M (2003) The mouse light/dark box test. Eur J Pharmacol 463:55-65. doi: 10.1016/S0014-2999(03)01274-3
5. Bovbjerg DH (2006) The continuing problem of post chemotherapy nausea and vomiting: contributions of classical conditioning. Auton Neurosci 129:92-98. doi: 10.1016/j.autneu.2006.07.016
6. Britton DR, Britton KT (1981) A sensitive open field measure of anxiolytic drug activity. Pharmacol Biochem Behav 15:577-582. doi: 10.1016/0091-3057(81)90212-4
7. Campos AC, Moreira FA, Gomes FV et al (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc B Biol Sci 367:3364-3378. doi: 10.1098/rstb.2011.0389
8. Campos D, Pereira JR, Reinhardt RR et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767
9. Cluny NL, Naylor RJ, Whittle BA, Javid FA (2011) The effects of cannabidiolic acid and cannabidiol on contractility of the gastrointestinal tract of Suncus murinus. Arch Pharm Res 34:1509-1517. doi: 10.1007/s12272-011-0913-6
10. Curzon P, Zhang M, Radek R, Fox G (2009) The behavioral assessment of sensorimotor processes in the mouse: acoustic startle, sensory gating, locomotor activity, rotarod, and beam walking. Methods Behav. Anal, Neurosci
11. Dos Santos LV, Souza FH, Brunetto AT et al (2012) Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104:1280-1292. doi: 10.1093/jnci/djs335
12. Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29:771-783. doi: 10.1016/j.neubiorev.2005.03.017
13. Duvvuri V, Risbrough VB, Kaye WH, Geyer MA (2009) 5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition. Pharmacol Biochem Behav 93:349-353. doi: 10.1016/j.pbb.2009.05.014
14. Farrimond JA, Hill AJ, Whalley BJ, Williams CM (2010a) Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats. Psychopharmacology (Berl) 210:97-106. doi: 10.1007/s00213-010-1821-z
15. 9tetrahydrocannabinol phytocannabinoids stimulate feeding in rats. Behav Pharmacol 23:113-117. doi: 10.1097/FBP.0b013e32834ed832
16. Farrimond JA, Whalley BJ, Williams CM (2012b) Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology (Berl) 223:117-129. doi: 10.1007/s00213-012-2697-x
17. Farrimond JA, Whalley BJ, Williams CM (2010b) A low-Δ9tetrahydrocannabinol cannabis extract induces hyperphagia in rats. Behav Pharmacol. doi: 10.1097/FBP.0b013e328340a062
18. Ferguson SA, Paule MG (1996) Effects of chlorpromazine and diazepam on time estimation behavior and motivation in rats. Pharmacol Biochem Behav 53:115-122. doi: 10.1016/0091-3057(95)02002-0
19. Figueroa-Moseley C, Jean-Pierre P, Roscoe JA et al (2007) Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 5:44-50
20. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (1999) Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT 1A receptor antagonists. Psychopharmacology (Berl) 144:121-130. doi: 10.1007/s002130050984
21. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (2000) The effects of compounds varying in selectivity as 5-HT1A receptor antagonists in three rat models of anxiety. Neuropharmacology 39:1848-1857. doi: 10.1016/S0028-3908(00)00074-5
22. Gross C, Santarelli L, Brunner D et al (2000) Altered fear circuits in 5-HT(1A) receptor KO mice. Biol Psychiatry 48:1157-1163. doi: 10.1016/S0006-3223(00)01041-6
23. Hainsworth JD, Hesketh PJ (1992) Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin Oncol 19:14-19
24. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-2494. doi: 10.1056/NEJMra0706547
25. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Gr. J Clin Oncol 21:4112-4119. doi: 10.1200/JCO.2003.01.095
26. Hickok JT, Roscoe JA, Morrow GR et al (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in treated in the community. Cancer 97:2880-2886. doi: 10.1002/cncr.11408
27. Hill AJ, Mercier MS, Hill TDM et al (2012) Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol 167:1629-1642. doi: 10.1111/j.1476-5381.2012.02207.x
28. Hill TDM, Cascio M-G, Romano B et al (2013) Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 170:679-692. doi: 10.1111/bph.12321
29. Janelsins MC, Tejani MA, Kamen C et al (2013) Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 14:757-766. doi: 10.1517/14656566.2013.776541
30. Kamen C, Tejani MA, Chandwani K et al (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722:172-179. doi: 10.1016/j.ejphar.2013.09.071
31. Kilkenny C, Browne W, Cuthill IC et al (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160:1577-1579. doi: 10.1111/j.1476-5381.2010.00872.x
32. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947. doi: 10.1200/JCO.2006.06.9591
33. Lotfi-Jam K, Carey M, Jefford M et al (2008) Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 26:5618-5629. doi: 10.1200/JCO.2007.15.9053
34. Malik IA, Khan WA, Qazilbash M et al (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18:170-175
35. Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53(Suppl 1):26-31. doi: 10.1159/000227637
36. Matteson S, Roscoe J, Hickok J, Morrow GR (2002) The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol 186:S239-S243. doi: 10.1067/mob.2002.122597
37. McGrath JC, Drummond GB, McLachlan EM et al (2010) Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160:1573-1576. doi: 10.1111/j.1476-5381.2010.00873.x
38. Meyer OA, Tilson HA, Byrd WC, Riley MT (1979) A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1:233-236
39. Navari RM, Reinhardt RR, Gralla RJ et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 340:190-195. doi: 10.1056/NEJM199901213400304
40. Nesse RM, Carli T, Curtis GC, Kleinman PD (1980) Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 42:33-36
41. Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463:3-33. doi: 10.1016/S0014-2999(03)01272-X
42. Razavi D, Delvaux N, Farvacques C et al (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11:1384-1390
43. Rex A, Voigt JP, Voits M, Fink H (1998) Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav 59:677-683. doi: 10.1016/S0091-3057(97)00461-9
44. Rock E, Parker L (2013a) Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol. doi: 10.1111/bph.12162
45. Rock EM, Limebeer CL, Navaratnam R et al (2014a) A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. Psychopharmacology (Berl). doi: 10.1007/s00213-014-3498-1
46. Rock EM, Limebeer CL, Parker LA (2014b) Anticipatory nausea in animal models: a review of potential novel therapeutic treatments. Exp Brain Res. doi: 10.1007/s00221-014-3942-9
47. Rock EM, Parker LA (2013b) Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid. Pharmacol Biochem Behav 111:84-89. doi: 10.1016/j.pbb.2013.08.012
48. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243. doi: 10.1093/annonc/mdq194
49. Roscoe JA, Morrow GR, Aapro MS et al (2011) Anticipatory nausea and vomiting. Support Care Cancer 19:1533-1538. doi: 10.1007/s00520-010-0980-0
50. Sánchez C (1996) 5-HT(1A) receptors play an important role in modulation of behavior of rats in a two-compartment black and white box. Behav Pharmacol 7:788-797
51. de Schier ARM, Ribeiro NP, Silva AC et al (2012) Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr 34(Suppl 1):S104-S110. doi: 10.1590/S1516-44462012000500008
52. Stanley JL, Lincoln RJ, Brown TA et al (2005) The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. J Psychopharmacol 19:221-227. doi: 10.1177/0269881105051524
53. Stephens N, Fearon K (2008) Anorexia, cachexia and nutrition. Medicine (Baltimore) 36:78-81. doi: 10.1016/j.mpmed.2007.11.004
54. Williams CM, Kirkham TC (2002) Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol Behav 76:241-250. doi: 10.1016/S0031-9384(02)00725-4
55. Williams CM, Rogers PJ, Kirkham TC (1998) Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 65:343-346. doi: 10.1016/S0031-9384(98)00170-X
56. Zhang J, Huang X-Y, Ye M-L et al (2010) Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J Neurosci 30:2433-2441. doi: 10.1523/JNEUROSCI.5880-09.2010